Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Virus-like particles |
| Clinical data | |
| Routes of administration | Intramuscular |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
|
Medical response |
|
 COVID-19 portal |
LYB001 is a COVID-19 vaccine candidate developed by Yantai Patronus Biotech Co., Ltd.[1][2][3][4]
References[edit]
- ^ "Safety, Reactogenicity, and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine LYB001 in healthy adults: a randomized, double blinded, placebo-controlled phase I trial". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 15 October 2021.
- ^ "A Phase I Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine LYB001". ClinicalTrials.gov. 18 November 2021. NCT05125926. Retrieved 18 November 2021.
- ^ "Immunogenicity and safety of a SARS-CoV-2 Vaccine LYB001 against COVID-19 in healthy adults: a randomized, double blinded, placebo-controlled phase II trial and a single-armed, open-label expanded safety phase III trial". chictr.org.cn. Chinese Clinical Trial Registry. Retrieved 15 October 2021.
- ^ "Phase II and III Trial of a SARS-CoV-2 Vaccine LYB001". ClinicalTrials.gov. 30 November 2021. NCT05137444. Retrieved 30 November 2021.
Scholia has a profile for LYB001 (Q110269779).
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
